AU2002245717A1 - Oligonucleotide conjugates - Google Patents

Oligonucleotide conjugates

Info

Publication number
AU2002245717A1
AU2002245717A1 AU2002245717A AU2002245717A AU2002245717A1 AU 2002245717 A1 AU2002245717 A1 AU 2002245717A1 AU 2002245717 A AU2002245717 A AU 2002245717A AU 2002245717 A AU2002245717 A AU 2002245717A AU 2002245717 A1 AU2002245717 A1 AU 2002245717A1
Authority
AU
Australia
Prior art keywords
oligonucleotide conjugates
conjugates
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002245717A
Other languages
English (en)
Inventor
Sergei Gryaznov
Gregg B. Morin
Krisztina Pongracz
Richard L. Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of AU2002245717A1 publication Critical patent/AU2002245717A1/en
Priority to AU2003244338A priority Critical patent/AU2003244338C1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B11/00—Diaryl- or thriarylmethane dyes
    • C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
    • C09B11/10—Amino derivatives of triarylmethanes
    • C09B11/24—Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2002245717A 2001-03-23 2002-03-21 Oligonucleotide conjugates Abandoned AU2002245717A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003244338A AU2003244338C1 (en) 2001-03-23 2003-09-02 Oligonucleotide conjugates

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27832201P 2001-03-23 2001-03-23
US60/278,322 2001-03-23
PCT/US2002/009138 WO2002077184A2 (en) 2001-03-23 2002-03-21 Oligonucleotide conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003244338A Division AU2003244338C1 (en) 2001-03-23 2003-09-02 Oligonucleotide conjugates

Publications (1)

Publication Number Publication Date
AU2002245717A1 true AU2002245717A1 (en) 2002-10-08

Family

ID=23064542

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002245717A Abandoned AU2002245717A1 (en) 2001-03-23 2002-03-21 Oligonucleotide conjugates

Country Status (5)

Country Link
EP (1) EP1379689B1 (enExample)
JP (1) JP4854913B2 (enExample)
AU (1) AU2002245717A1 (enExample)
CA (1) CA2440322C (enExample)
WO (1) WO2002077184A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
TW200540180A (en) * 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
RS56361B1 (sr) 2004-07-02 2017-12-29 Geron Corp Sinteza zaštićenih 3'-amino nukleozidnih monomera
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
CA2925500C (en) 2013-09-30 2023-03-14 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
MA42569B1 (fr) 2015-04-23 2020-08-31 Geron Corp Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
TWI879717B (zh) 2017-07-28 2025-04-11 美商傑龍公司 治療骨髓增生不良症候群之方法
SG11202105573PA (en) 2018-11-29 2021-06-29 Geron Corp Methods of treating myelodysplastic syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965349A (en) * 1987-12-24 1990-10-23 Applied Biosystems, Inc. Method of synthesizing oligonucleotides labeled with ammonia-labile groups on solid phase supports
US5352803A (en) * 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
US5863726A (en) * 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
JP3189000B2 (ja) * 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US6425604B1 (en) * 1999-02-23 2002-07-30 Recreational Technologies International, Llc Vehicle leveling assembly
AU767646B2 (en) * 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use

Also Published As

Publication number Publication date
HK1065063A1 (en) 2005-02-08
CA2440322C (en) 2014-09-09
EP1379689A2 (en) 2004-01-14
CA2440322A1 (en) 2002-10-03
WO2002077184A3 (en) 2003-03-20
EP1379689B1 (en) 2012-09-26
EP1379689A4 (en) 2004-04-14
JP2004526737A (ja) 2004-09-02
JP4854913B2 (ja) 2012-01-18
WO2002077184A2 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
WO2003018621A8 (en) Genes
AU2003278857A1 (en) Oligonucleotide conjugates
AU2002313565A1 (en) Putter-heads
AU2002245717A1 (en) Oligonucleotide conjugates
GB0119665D0 (en) Conjugates
AU2002319532A1 (en) Feeding-bottles
AU2002313943A1 (en) Electromobile
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AU2002313073A1 (en) Phytocystatin
AU2002257925A1 (en) Numberplates
AU2001100532A4 (en) FonePark
AU2001100338A4 (en) Sunglove
AU2001100214A4 (en) Dolly-trolley
AU2001100522A4 (en) e-Trans
AU2002100746A4 (en) Adrail
AU2002224013A1 (en) Bone-cracking implement
AUPR325301A0 (en) Easy build - mpt - system
AU2002308879A1 (en) Stat6-activating genes
AU2002234456A1 (en) Enhanced pickup-electrode
AUPR383801A0 (en) Increased superannuation
AUPR243601A0 (en) Improvements
AUPR409801A0 (en) Improvements
AU2002253687A1 (en) Floss-pick
AU2002316748A1 (en) S-6-hydroxy-buspirone

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase